ArticleInvestigational new drugs2019

Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.

Inhwan Hwang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.